trending Market Intelligence /marketintelligence/en/news-insights/trending/0A5YjRns1bOdaV4-fhV25Q2 content esgSubNav
In This List

Ovid Therapeutics drug gets FDA orphan drug status for rare epilepsy disorder

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Ovid Therapeutics drug gets FDA orphan drug status for rare epilepsy disorder

The U.S. Food and Drug Administration granted orphan drug designation to Ovid Therapeutics Inc.'s TAK-935/OV935 to treat Lennox-Gastaut syndrome, a rare form of epilepsy.

In January, Takeda Pharmaceutical Co. Ltd. and Ovid formed a global collaboration to develop and commercialize TAK-935/OV935 to treat developmental and epileptic encephalopathies, a group of rare epilepsies that cause morbidities and can worsen over time.

The agency previously granted orphan drug status to the drug for the treatment of Dravet syndrome, another rare form of epilepsy.